Compare HCA Health Inc (HCA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? HCA Health Inc trades at $406.5 (market cap $89.76B), while State Street SPDR S&P Biotech ETF trades at $158.74. The key difference: HCA Health Inc pays a 0.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| HCA | XBI | |
|---|---|---|
Market Cap | $89.76B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $545.13 | $164.28 |
52-Week Low | $361.32 | $88.79 |
Enterprise Value | $140.30B | — |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.66, up 0.15% today, with a bullish technical signal from moving averages and a P/E of 13.8. Revenue grew to $75.60B in 2025, with net income of $6.78B, and the company has beaten EPS estimates for three consecutive quarters. Recent corporate actions include a $0.78 dividend scheduled for September 2026.
The outlook is positive with a consensus price target of $449.93, implying 8.5% upside, supported by strong earnings and institutional buy ratings. Risks include high debt levels, regulatory investigations, and expense pressures noted in Q2 2026 results. Investors should weigh solid fundamentals against legal and operational headwinds.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
